NEW YORK (GenomeWeb) – HTG Molecular Diagnostics and Qiagen Manchester Ltd., a wholly owned subsidiary of Qiagen, said today that they have inked a master assay development, commercialization, and manufacturing agreement.

The agreement creates a framework for the companies to combine their technological and commercial strengths to offer pharmaceutical companies a complete next-generation sequencing-based solution for the development and commercialization of companion diagnostic tests, with a focus on oncology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sep
20

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep
28

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.